Cost-effectiveness estimates for antenatal HIV testing in the Netherlands

M.H. Rozenbaum, G. Verweel, D.K.F. Folkerts, F. Dronkers, J.A.R. van den Hoek, N.G. Hartwig, R. de Groot, M.J. Postma

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Scopus)

Abstract

This paper provides an estimation of the lifetime health-care cost of HIV-infected children and an update of the cost-effectiveness of universal HIV-screening of pregnant women in Amsterdam (The Netherlands). During 2003-2005, we collected data concerning the prevalence of newly diagnosed HIV-infected pregnant women in Amsterdam. Also, data on resource utilization and HAART regimen for HIV-infected children was gathered from a national registry. Using Kaplan-Meier survival analysis, we estimated the life-expectancy of a vertically HIV-infected child at 19 years, with the corresponding lifetime health-care costs of "sic"179,974. HIV-screening of pregnant women could prevent 2.4 HIV transmissions annually in Amsterdam, based on an estimated prevalence of nine yet undiagnosed HIV-positive pregnant women per 10,000 pregnancies. We show that universal HIV screening during pregnancy generates significant net cost savings and health benefits in most situations. Universal antenatal HIV screening is justified in Amsterdam from a health-economic point of view.

Original languageEnglish
Pages (from-to)668-675
Number of pages8
JournalInternational Journal of STD & AIDS
Volume19
Issue number10
DOIs
Publication statusPublished - Oct-2008

Keywords

  • AIDS
  • cost-effectiveness analyses
  • mother-to-child transmission
  • antenatal HIV-screening
  • health economics
  • HUMAN-IMMUNODEFICIENCY-VIRUS
  • ACTIVE ANTIRETROVIRAL THERAPY
  • HEALTH-CARE UTILIZATION
  • TO-CHILD TRANSMISSION
  • PREGNANT-WOMEN
  • HIV-1-INFECTED MOTHERS
  • VERTICAL TRANSMISSION
  • UNINFECTED CHILDREN
  • INFECTED PATIENTS
  • CELL COUNTS

Cite this